We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A new transceiver chip designed by Zarlink Semiconductor enables medical devices and base stations to communicate with each other over a wireless connection, providing physicians with the ability to remotely monitor patients, the company said last week.
Along with U.S. companies such as Medtronic and Abbott, international companies are also vying for a piece of the drug-eluting stent (DES) market currently dominated by Boston Scientific and Johnson & Johnson as evidenced by the presentations at the Paris Course on Revascularization (EuroPCR) meeting.
Follow-up clinical data from Conor Medsystem’s EuroSTAR (EUROpean cobalt chromium STent with Antiproliferative for Restenosis) study demonstrate a low incidence of both target lesion revascularization (TLR) and major adverse cardiac events (MACE), the company announced last week.
Medical devicemaker Guidant has acknowledged it neglected to tell patients or physicians about a defibrillator flaw that has caused a small number of the company’s units to malfunction.
America’s two largest drug-eluting stent makers presented promising results in clinical trials of their products in high-risk patients last week at the annual Paris Course on Revascularization (EuroPCR).
A clinical trial that will measure and gather data on the breathing patterns of children with cystic fibrosis (CF) will soon evaluate the effectiveness of VivoMetrics’ LifeShirt System specifically for pediatric patients.
Cyberonics CEO Robert Cummins is firing back against negative publicity resulting from a Senate Finance Committee probe into the FDA’s handling of the company’s application to market an existing device to treat patients with major depressive disorders.
Conor Medsystem’s UniStar cobalt chromium bare-metal coronary stent received the EU's CE mark approval for the treatment of de novo coronary artery lesions, the stent maker announced last week.